美国、欧盟与加拿大放射性药物首次人体试验监管要求的协调是否可行
本文为教育性综述,概述欧洲与北美对研究性放射性药物首次人体试验的监管与申报要求差异,指出差异常源于法域政策而非科学证据,可阻碍全球合作、增加费用并延缓进展。作者希望通过持续协作实现监管改革与协调,加快患者获得最新循证诊疗。
要点
- 放射性药物首次人体试验的美欧加监管要求存在差异,常基于法域政策而非科学证据。
- 核医学倡导组织、监管机构与国际机构已开始识别监管共性以推动协调。
- 通过建立统一的临床前研究与生产标准要求,可能实现放射性药物研发的简化路径。
核心结论
- 本文为教育性综述,指出美欧加对研究性放射性药物首次人体试验的监管与申报要求存在差异,希望通过持续协作实现监管改革与协调,加快患者获得最新循证诊疗。
研究设计与样本
- 教育性综述,概述欧洲与北美大陆对研究性放射性药物首次人体试验的监管与申报要求。
主要发现
- 近年来已开发多种新型放射性示踪剂与放射性核素治疗药物,核医学与分子影像处于复兴时期,例如神经内分泌肿瘤与前列腺恶性肿瘤的显像与治疗能力。
- 监管要求差异常基于法域政策而非科学证据,可阻碍全球合作、增加费用并延缓进展。
- 核医学倡导组织、监管机构与国际机构已开始识别监管共性以实现协调。
- 通过建立统一的临床前研究与生产标准要求,可能实现跨法域放射性药物研发的更简化路径。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In recent years, several new radiotracers and radionuclide therapies have been developed. There is a renaissance in nuclear medicine and molecular imaging today, for example, in terms of the ability to image and treat neuroendocrine and prostate malignancies. In order to be able to bring a new drug product from bench to bedside and assist patients, while also ensuring patient safety, stringent regulations must be met. However, differences in regulatory requirements, often based on jurisdictional politics rather than scientific evidence, can hinder global co-operation, increase expense, and slow progress. In an effort to rise above these differences, nuclear medicine advocacy organizations, regulators, and international agencies have begun to identify commonalities in the regulations to achieve harmonization. Indeed, a more streamlined approach to radiopharmaceutical drug development across jurisdictions could be achieved through establishing harmonized requirements for pre-clinical studies and manufacturing standards. This paper provides an educational overview of the regulatory and submission requirements governing investigational radiopharmaceuticals for first-in-human radiopharmaceuticals across the European and North American continents. It is hoped that through ongoing collaboration, regulatory reform and harmonization can become a reality and speed access to the most up-to-date evidence-based patient care for all.
引用
- Schwarz SW, Decristoforo C, Goodbody AE, et al. Harmonization of United States, European Union and Canadian First-in-Human Regulatory Requirements for Radiopharmaceuticals-Is This Possible? J Nucl Med. 2018. PMID: 30262520. doi:10.2967/jnumed.118.209460
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。